Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
NCT03414047Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of prexasertib in ovarian cancer, sponsored by Eli Lilly and Company. Started Apr 2018; status: completed.
02
Drugs
prexasertib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03414047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414047.